Rationale, design and baseline characteristics of the Personalised prospective comparison of ARni with ArB in patients with natriuretic peptide eLEvation (PARABLE) randomized controlled trial

被引：0
|
作者：
Ledwidge, M. [1 ]
Ryan, F. [1 ]
Watson, C. [1 ]
Gallagher, J. [1 ]
Ferre, M. [1 ]
Pharithi, R. [1 ]
Barrett, M. [1 ]
Murphy, D. [2 ]
Dodd, J. [2 ]
Mcdonald, K. M. [1 ]
机构：
[1] St Vincents Univ Hosp, STOP HF Unit, Dublin, Ireland
[2] St Vincents Univ Hosp, Dept Radiol, Dublin, Ireland
来源：
EUROPEAN JOURNAL OF HEART FAILURE | 2019年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P1176
引用
收藏
页码：291 / 292
页数：2
相关论文
共 50 条
  • [1] PROGRESSION OF DOPPLER-ECHOCARDIOGRAPHIC MARKERS OF STRUCTURE AND FUNCTION IN THE PERSONALISED PROSPECTIVE COMPARISON OF ARNI WITH ARB IN PATIENTS WITH NATRIURETIC PEPTIDE ELEVATION (PARABLE) RANDOMIZED CONTROLLED TRIAL
    Ledwidge, M.
    Pharithi, R. B.
    Ryan, F.
    Dodd, J.
    Murphy, D.
    Gallagher, J.
    Watson, C.
    Barrett, M.
    McDonald, K.
    Ferre, M.
    HEART, 2019, 105 : A16 - A17
  • [2] Progression of markers of cardiac structure and function in the Personalised prospective comparison of ARni with ArB in patients with natriuretic peptide eLEvation (PARABLE) clinical trial
    Ledwidge, M.
    Ryan, F.
    Watson, C.
    Gallagher, J.
    Pharithi, R.
    Ferre, M.
    Murphy, D.
    Barrett, M.
    Dodd, J.
    Mcdonald, K. M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 139 - 139
  • [3] Rationale, design, and baseline characteristics of the Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial (PREVENT)
    Byington, RP
    Miller, ME
    Herrington, D
    Riley, W
    Pitt, B
    Furberg, CD
    Hunninghake, DB
    Mancini, GBJ
    AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (08): : 1087 - &
  • [4] Design, rationale, and baseline characteristics of a cluster randomized controlled trial of pay for performance for hypertension treatment: study protocol
    Petersen, Laura A.
    Urech, Tracy
    Simpson, Kate
    Pietz, Kenneth
    Hysong, Sylvia J.
    Profit, Jochen
    Conrad, Douglas
    Dudley, R. Adams
    Lutschg, Meghan Z.
    Petzel, Robert
    Woodard, LeChauncy D.
    IMPLEMENTATION SCIENCE, 2011, 6
  • [5] Design, rationale, and baseline characteristics of a cluster randomized controlled trial of pay for performance for hypertension treatment: study protocol
    Laura A Petersen
    Tracy Urech
    Kate Simpson
    Kenneth Pietz
    Sylvia J Hysong
    Jochen Profit
    Douglas Conrad
    R Adams Dudley
    Meghan Z Lutschg
    Robert Petzel
    LeChauncy D Woodard
    Implementation Science, 6
  • [6] Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-A randomized placebo-controlled trial
    Neal, Bruce
    Perkovic, Vlado
    de Zeeuw, Dick
    Mahaffey, Kenneth W.
    Fulcher, Greg
    Stein, Peter
    Desai, Mehul
    Shaw, Wayne
    Jiang, Joel
    Vercruysse, Frank
    Meininger, Gary
    Matthews, David
    AMERICAN HEART JOURNAL, 2013, 166 (02) : 217 - +
  • [7] Rationale, Design and Baseline Characteristics of a Randomized Controlled Trial of a Cardiovascular Quality Improvement Strategy in India: The C-QIP Trial
    Singh, Kavita
    Nikhar, Kalyani
    Gandral, Mar eesha
    Aithal, Kiran
    Patil, Satish G.
    Girish, M. P.
    Gupta, Mohit
    Madan, Kushal
    Sawhney, J. P. S.
    Ali, Kamar
    Kondal, Dimple
    Jindal, Devraj
    Mendenhall, Emily
    Patel, Shivani A.
    Narayan, K. M. Venkat
    Tandon, Nikhil
    Roy, Ambuj
    Huffman, Mark D.
    Prabhakaran, Dorairaj
    AMERICAN HEART JOURNAL, 2024, 276 : 83 - 98
  • [8] The Diabetes Health Coaching Randomized Controlled Trial: Rationale, Design and Baseline Characteristics of Adults Living With Type 2 Diabetes
    Sherifali, Diana
    Brozic, Anka
    Agema, Pieter
    Gerstein, Hertzel C.
    Punthakee, Zubin
    McInnes, Natalia
    O'Reilly, Dania
    Ibrahim, Sarah
    Ali, R. Muhammad Usman
    CANADIAN JOURNAL OF DIABETES, 2019, 43 (07) : 477 - 482
  • [9] A randomized controlled trial to evaluate the safety and efficacy of cardiac contractility modulation in patients with systolic heart failure: Rationale, design, and baseline patient characteristics
    Abraham, William T.
    Burkhoff, Daniel
    Nademance, Koonlawee
    Carson, Peter
    Bourge, Robert
    Ellenbogen, Kenneth A.
    Parides, Michael
    Kadish, Alan
    AMERICAN HEART JOURNAL, 2008, 156 (04) : 641 - 648
  • [10] Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
    Bernard Zinman
    Silvio E Inzucchi
    John M Lachin
    Christoph Wanner
    Roberto Ferrari
    David Fitchett
    Erich Bluhmki
    Stefan Hantel
    Joan Kempthorne-Rawson
    Jennifer Newman
    Odd Erik Johansen
    Hans-Juergen Woerle
    Uli C Broedl
    Cardiovascular Diabetology, 13
12345